ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
65.86
-0.35 (-0.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close66.21
Open65.08
Bid0.00 x 1000
Ask0.00 x 800
Day's Range65.12 - 67.18
52 Week Range58.21 - 133.74
Volume391,680
Avg. Volume605,031
Market Cap2.153B
Beta (3Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-10.44
Earnings DateOct 29, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est150.90
Trade prices are not sourced from all markets
  • Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions
    Investor's Business Daily

    Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions

    The NASH liver disease treatment market is growing with biotech companies like Intercept and Genfit in late-stage tests. Experts say the market for a successful drug could be worth billions.

  • Thomson Reuters StreetEvents

    Edited Transcript of ICPT earnings conference call or presentation 7-Aug-19 12:30pm GMT

    Q2 2019 Intercept Pharmaceuticals Inc Earnings Call

  • Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
    Zacks

    Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus

    Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.

  • Investors Who Bought Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Five Years Ago Are Now Down 79%
    Simply Wall St.

    Investors Who Bought Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Five Years Ago Are Now Down 79%

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

  • Intercept Pharmaceuticals Inc (ICPT) Q2 2019 Earnings Call Transcript
    Motley Fool

    Intercept Pharmaceuticals Inc (ICPT) Q2 2019 Earnings Call Transcript

    ICPT earnings call for the period ending June 30, 2019.

  • What You'll Want to Know About Intercept Pharmaceuticals' Q2 Update
    Motley Fool

    What You'll Want to Know About Intercept Pharmaceuticals' Q2 Update

    The drugmaker reported strong sales growth for Ocaliva as it prepares to file for approval in what could be a blockbuster indication.

  • Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates

    Intercept (ICPT) delivered earnings and revenue surprises of 9.16% and 12.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

    Company delivers strongest quarter to date with worldwide Ocaliva® net sales of $65.9 million in the second quarter of 2019, representing 53% growth versus the prior year.

  • GlobeNewswire

    Intercept to Announce Second Quarter 2019 Financial Results on August 7, 2019

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2019 financial results prior to market open on Wednesday, August 7, 2019. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

  • Will Intercept Pharmaceuticals (ICPT) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will Intercept Pharmaceuticals (ICPT) Report Negative Q2 Earnings? What You Should Know

    Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 3 Top Healthcare Stocks to Buy in July
    Motley Fool

    3 Top Healthcare Stocks to Buy in July

    Find out which stocks have our team of healthcare experts feeling excited right now.

  • 4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts
    TipRanks

    4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts

    Investing in biotech stocks can generate substantial returns. If data results meet key targets, or drug applications are accepted, share prices can soar. Unfortunately the reverse is also true. That means investors have to be particularly careful when it comes to biotech stocks. The following four stocks all show a Strong Buy Street consensus- based on ratings received over the last three months. They also boast significant upcoming catalysts this quarter- that could potentially send share prices soaring. Let’s take a closer look at each stock now: 1\. Intercept Pharmaceuticals (ICPT)Intercept Pharma is trying to help patients with progressive non-viral liver diseases. The company already has one drug on the market (for primary biliary cirrhosis), and recently released positive results from the Phase 3 REGENERATE trial in NASH Fibrosis. Nash is a chronic condition in which the buildup of fat and inflammation in the liver may eventually lead to severe scarring called fibrosis. It is currently the second leading cause of liver transplant in the US- making it a very lucrative opportunity for drug companies. Intercept has an early mover advantage here. The company plans to submit an NDA [new drug application] in 3Q19 and an MAA [marketing authorization application] in 4Q19. “Obeticholic Acid will likely be the first to market in NASH and is the only drug to have demonstrated a fibrosis benefit” cheers Needham analyst Alan Carr. “We acknowledge certain potential safety and tolerability limitations, but nevertheless expect the drug to have an important role in NASH therapy over the next several years” says the analyst. Overall the stock has a ‘Strong Buy’ Street consensus, with 5 recent buy ratings vs just 1 hold rating. Meanwhile the average analyst price target of $148 indicates huge upside potential of 113%. >>Click Here to see the full list of ICPT Analyst Ratings 2\. Rhythm Pharmaceuticals (RYTM)Rhythm is developing treatments for rare genetic deficiencies that result in life-threatening metabolic disorders. The big news here is that Rhythm is expected to announce results in 3Q19 from two Phase 3 trials of setmelanotide in POMC and LEPR Deficiency. There are currently no approved drugs for these diseases- and no other drugs in development.“We anticipate a positive outcome for both trials based on Phase 2 data demonstrating a profound and durable impact on appetite and weight” writes Carr. The analyst assumes US approval and launch in 4Q20 (EU 2021) and peak worldwide sales of around $265M in 2032.“Considering recent weakness, we believe the stock is attractive ahead of Phase 3 POMC and LEPR Deficiency trial results. We believe there is even more room for upside for the stock as the company completes label expansion trials in 2020+” enthuses Carr. Most notably label expansion Phase 3 trial in Bardet-Biedl/Alstrom Syndromes remains on track for results in 2H20. Success here adds another $485M in peak sales potential. “Additional patient populations under evaluation in a Phase 2 trial push peak sales above $1B” writes Carr. RYTM has four consecutive recent buy ratings from the Street, with an average price target of $40 (95% upside potential). >>Click Here to see the full list of RYTM Analyst Ratings 3\. Moderna Inc (MRNA)Moderna is hoping to create a new generation of transformative medicines for patients. The company’s approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease. Encouragingly, all seven analysts covering MRNA rate the stock a buy- so no hold or sell ratings here. “We expect Moderna to provide updates on Cytomegalovirus (CMV), Chikungunya, and Methylmalonic Acidemia (MMA) programs by YE19” writes the analyst.While the commercial opportunity in Chikungunya is modest, he believes PK/PD data from the Phase 1 trial will provide valuable insight into the overall predictability of several other mRNA drugs in development at the company.“The stock has fallen substantially from its peak in May 2019. We believe there is an opportunity for upside in 2H19 as the company announces data from the above CMV, Chikungunya, and MMA programs” Carr concludes. Indeed, the Street’s $30 average price target suggests share prices can double in the coming months. >>Click Here to see the full list of MRNA Analyst Ratings 4\. Cara Therapeutics (CARA)Cara Therapeutics has surged 30% in last the three months. In May the company announced positive results from the first of two Phase 3 trials of IV Korsuva in Chronic Kidney Disease (CKD) dialysis patients with pruritus. Pruritus refers to the severe itching of the skin, a common and distressing symptom for patients with chronic kidney disease. Cara Therapeutics CEO Derek Chalmers noted at the time that the company was "particularly encouraged by the early [anti-itching] response with Korsuva injection." Now investors are keeping a close eye on results from the second trial (KALM-2) and from a Phase 2 trial of oral Korsuva in non-dialysis patients with CKD pruritus- both expected in 2H19. “We anticipate a positive outcome for both trials” comments Carr, adding that the recent results point to a favorable outcome for the KALM-2 trial. “We believe the outcome is also a positive indicator for the oral Korsuva programs in CKD pruritus, Liver Disease pruritus, and Atopic Dermatitis, all of which have large commercial opportunities.”Bottom line: “The stock is substantially undervalued.” All six analysts polled are bullish on CARA right now. Meanwhile the average analyst price target stands at $33 (30% upside potential). >>Click Here to see the full list of CARA Analyst RatingsDiscover the latest ratings from top analysts in any sector you choose

  • Better Buy: Intercept Pharmaceuticals vs. CV Sciences
    Motley Fool

    Better Buy: Intercept Pharmaceuticals vs. CV Sciences

    Which stock wins in a battle between an up-and-coming biotech and a hemp CBD leader?

  • An Intrinsic Calculation For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Suggests It's 43% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Suggests It's 43% Undervalued

    How far off is Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) from its intrinsic value? Using the most recent financial...

  • Markit

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ICPT are favorable, with net inflows of $3.04 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzinga

    ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention

    ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) shares were rallying Monday on positive news related to its non-alcoholic steatohepatitis, or NASH, drug. ContraVir, which came under pressure Friday following ...

  • Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor
    Market Realist

    Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor

    Intercept Pharmaceuticals (ICPT) closed at $80.99 on June 12, 0.90% higher than its previous close, 10.93% above its 52-week low of $73.01, and 39.44% below its 52-week high of $133.74.

  • Is Intercept Pharmaceuticals Inc (ICPT) A Good Stock To Buy?
    Insider Monkey

    Is Intercept Pharmaceuticals Inc (ICPT) A Good Stock To Buy?

    "The end to the U.S. Government shutdown, reports of progress on China-U.S. trade talks, and the Federal Reserve’s confirmation that it did not plan further interest rate hikes in 2019 allayed investor fears and drove U.S. markets substantially higher in the first quarter of the year. Global markets followed suit pretty much across the board […]

  • CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
    Zacks

    CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

    CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.

  • MarketWatch

    CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors

    Shares of CymaBay Therapeutics Inc. plummeted 43% in premarket trade Tuesday after the biotech said data from an ongoing Phase 2 trial showed patients with nonalcoholic steatohepatitis (NASH) who were treated with investigational drug seladelpar did not show significant reductions in liver fat when compared with those on a placebo. However, treatment with seladelpar did result in a reduction in biomarkers associated with liver injury, the company said. "While the reductions in liver fat were minimal, we remain encouraged by the significant improvements in biochemical markers of liver injury that we observed at week 12," said Pol Boudes, CymaBay's chief medical officer. "The 52-week liver biopsy data will allow us to understand whether the improvement in liver injury markers will translate into histological improvement. The observed improvement in markers of liver injury are consistent with the observed effects of seladelpar in PBC and further support the potential for seladelpar to improve liver health." In NASH, fat builds up in the liver, triggering inflammation and cell injury that can lead to serious complications like cirrhosis, or liver scarring. There have been several trial updates in the NASH space so far this year from companies like Gilead Sciences Inc. and Intercept Pharmaceuticals Inc. , but they have not been promising, according to Jefferies health desk trader Jared Holz. "Investors have not been impressed with current data," he wrote in a note to clients Tuesday morning. Shares of CymaBay Therapeutics Inc. have gained 41% in the year to date through Monday, while the S&P 500 has gained 15%.

  • Why Is Intercept (ICPT) Down 5.2% Since Last Earnings Report?
    Zacks

    Why Is Intercept (ICPT) Down 5.2% Since Last Earnings Report?

    Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Biotech Stocks Tumble As FDA Doubts Method Of Testing Drugs
    Investor's Business Daily

    Biotech Stocks Tumble As FDA Doubts Method Of Testing Drugs

    Biotech stocks Intercept Pharmaceuticals and Madrigal Pharmaceuticals were hit Thursday after the Food and Drug Administration cast doubt on a method of evaluating some liver disease drugs.

  • Benzinga

    ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study

    Shares of the nano-cap, thinly traded biotech  ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) were trading nearly 150-percent higher Thursday.  What Happened ContraVir, which focuses on therapies for liver ...